BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 9632724)

  • 1. Critical role for the 310 helix region of p57(Kip2) in cyclin-dependent kinase 2 inhibition and growth suppression.
    Hashimoto Y; Kohri K; Kaneko Y; Morisaki H; Kato T; Ikeda K; Nakanishi M
    J Biol Chem; 1998 Jun; 273(26):16544-50. PubMed ID: 9632724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cell cycle-regulated B-Myb transcription factor overcomes cyclin-dependent kinase inhibitory activity of p57(KIP2) by interacting with its cyclin-binding domain.
    Joaquin M; Watson RJ
    J Biol Chem; 2003 Nov; 278(45):44255-64. PubMed ID: 12947099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual cyclin-binding domains are required for p107 to function as a kinase inhibitor.
    Castaño E; Kleyner Y; Dynlacht BD
    Mol Cell Biol; 1998 Sep; 18(9):5380-91. PubMed ID: 9710622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p57(Kip2) stabilizes the MyoD protein by inhibiting cyclin E-Cdk2 kinase activity in growing myoblasts.
    Reynaud EG; Pelpel K; Guillier M; Leibovitch MP; Leibovitch SA
    Mol Cell Biol; 1999 Nov; 19(11):7621-9. PubMed ID: 10523650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin D- and E-dependent kinases and the p57(KIP2) inhibitor: cooperative interactions in vivo.
    Gómez Lahoz E; Liegeois NJ; Zhang P; Engelman JA; Horner J; Silverman A; Burde R; Roussel MF; Sherr CJ; Elledge SJ; DePinho RA
    Mol Cell Biol; 1999 Jan; 19(1):353-63. PubMed ID: 9858559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor Tomudex.
    Yin MB; Guo B; Panadero A; Frank C; Wrzosek C; Slocum HK; Rustum YM
    Exp Cell Res; 1999 Feb; 247(1):189-99. PubMed ID: 10047461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete inhibition of Cdk/cyclin by one molecule of p21(Cip1).
    Hengst L; Göpfert U; Lashuel HA; Reed SI
    Genes Dev; 1998 Dec; 12(24):3882-8. PubMed ID: 9869641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells.
    Orend G; Hunter T; Ruoslahti E
    Oncogene; 1998 May; 16(20):2575-83. PubMed ID: 9632134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of Cdk2/Cyclin E inhibition by p27 and p27 phosphorylation.
    Xu X; Nakano T; Wick S; Dubay M; Brizuela L
    Biochemistry; 1999 Jul; 38(27):8713-22. PubMed ID: 10393546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution.
    Lee MH; Reynisdóttir I; Massagué J
    Genes Dev; 1995 Mar; 9(6):639-49. PubMed ID: 7729683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of G1 phase arrest in MCF human breast cancer cells by pentagalloylglucose through the down-regulation of CDK4 and CDK2 activities and up-regulation of the CDK inhibitors p27(Kip) and p21(Cip).
    Chen WJ; Chang CY; Lin JK
    Biochem Pharmacol; 2003 Jun; 65(11):1777-85. PubMed ID: 12781329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57KIP2 requires binding to proliferating cell nuclear antigen.
    Watanabe H; Pan ZQ; Schreiber-Agus N; DePinho RA; Hurwitz J; Xiong Y
    Proc Natl Acad Sci U S A; 1998 Feb; 95(4):1392-7. PubMed ID: 9465025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of p27(Kip1) in human intestinal cell differentiation.
    Deschênes C; Vézina A; Beaulieu JF; Rivard N
    Gastroenterology; 2001 Feb; 120(2):423-38. PubMed ID: 11159883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
    Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
    Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of nuclear transport and degradation of the Xenopus cyclin-dependent kinase inhibitor, p27Xic1.
    Chuang LC; Yew PR
    J Biol Chem; 2001 Jan; 276(2):1610-7. PubMed ID: 11044455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The amino terminus of Cdk2 binds p21.
    Moskowitz NK; Borao FJ; Dardashti O; Cohen HD; Germino FJ
    Oncol Res; 1996; 8(9):343-52. PubMed ID: 8979268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p21 contains independent binding sites for cyclin and cdk2: both sites are required to inhibit cdk2 kinase activity.
    Fotedar R; Fitzgerald P; Rousselle T; Cannella D; Dorée M; Messier H; Fotedar A
    Oncogene; 1996 May; 12(10):2155-64. PubMed ID: 8668341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex.
    Russo AA; Jeffrey PD; Patten AK; Massagué J; Pavletich NP
    Nature; 1996 Jul; 382(6589):325-31. PubMed ID: 8684460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins.
    Sangfelt O; Erickson S; Castro J; Heiden T; Gustafsson A; Einhorn S; Grandér D
    Oncogene; 1999 May; 18(18):2798-810. PubMed ID: 10362250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential interaction of the cyclin-dependent kinase (Cdk) inhibitor p27Kip1 with cyclin A-Cdk2 and cyclin D2-Cdk4.
    Blain SW; Montalvo E; Massagué J
    J Biol Chem; 1997 Oct; 272(41):25863-72. PubMed ID: 9325318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.